Table 4.
Resistance profile of clinical isolates causing secondary infections in COVID-19 patients.
| Sample Type Number of samples (%) |
Blood 39 (37.1%) |
Urine 18 (17.1) |
Respiratory samples 32 (30.5%) |
Pus 12 (11.4%) |
Others 4 (3.8%) |
Total 105 |
|
|---|---|---|---|---|---|---|---|
| Antimicrobials | Amikacin | 29 (74.4%) | 0 (0%) | 16 (50%) | 2 (16.7%) | 1 (25%) | 48 (46%) |
| Amoxicillin/Clavulanic Acid | 39 (100.0%) | 18 (100%) | 21 (65.6%) | 6 (50%) | 4 (100%) | 88 (84%) | |
| Ampicillin | 39 (100.0%) | 18 (100%) | 0 | 9 (75%) | 4 (100%) | 70 (67%) | |
| Caspofungin# | NT | 0 | NT | NT | NT | 0 | |
| Cefepime | 37 (94.9%) | 0 | 26 (81%) | 5 (41.7%) | 4 (100%) | 72 (69%) | |
| Cefoperazone/Sulbactam | 36 (92.3%) | 5 (25%) | 22 (69%) | 5 (41.7%) | 4 (100%) | 72 (69%) | |
| Ceftazidime | 36 (92.3%) | 0 | 27 (84.4%) | 0 | 4 (100%) | 67 (64%) | |
| Ciprofloxacin | 38 (97.4%) | 3 (16.70%) | 28 (88%) | 10 (83.3%) | 4 (100%) | 83 (79%) | |
| Colistin∗ | 3 (7.7%) | 0 | 3 (9.37%) | 3 (25%) | 0 |
9 (9%) | |
| Fluconazole# | NT | 0 | NT | NT | NT | 0 | |
| Imipenem | 36 (92.3%) | 0 | 24 (75%) | 5 (41.7%) | 2 (50%) | 67 (64%) | |
| Levofloxacin | 36 (92.3%) | 5 (25%) | 30 (94%) | 12 (100%) | 4 (100%) | 87 (83%) | |
| Meropenem | 37 (94.9%) | 3 (14.30%) | 26 (81%) | 4 (33.3%) | 2 (50%) | 72 (69%) | |
| Nitrofurantoin | 28 (71.8%) | 9 (50%) | 0 | 8 (66.7%) | 4 (100%) | 49 (47%) | |
| Piperacillin/Tazobactam | 38 (97.4%) | 3 (16.70%) | 29 (91%) | 7 (58.3%) | 4 (100%) | 81 (77%) | |
| Tigecycline | 14 (35.9%) | 0 | 17 (53%) | 3 (25%) | 1 (25%) | 35 (33%) | |
| Trimethoprim/Sulfamethoxazole | 37.00% (94.9%) | 6 (33.30%) | 24 (75%) | 8 (66.7%) | 4 (100%) | 79 (75%) | |
#; Antifungal., NT; Not Tested, ∗; The minimum inhibitor concentration for colistin was tested by the broth microdilution method as per the joint guidelines of EUCAST-CLSI. The resistance profile is depicted as the number of resistant isolates and percentages.